SynthesisActa oncologica (Stockholm, Sweden)2026
Prevalence and risk factors for nausea and vomiting in breast cancer patients undergoing chemotherapy.
Synthesis in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline neutrophil-to-lymphocyte ratio is not associated with chemotherapy-induced nausea and vomiting in patients with breast cancer: A single-center retrospective cohort study.Experimental and therapeutic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeChemotherapy-induced nausea and vomiting (CINV) is a common and severe adverse effect of breast cancer (BC) treatment that compromises treatment adherence and quality of life. This meta-analysis aims to assess the prevalence and risk factors of CINV in BC patients, thereby providing clinical insights for its prevention and improvement. Patient/material and methods: Relevant literature was identified through an extensive search of electronic databases from their inception up to July 10, 2025: PubMed, Web of Science, Embase, Cochrane, CNKI, Wanfang, and VIP databases on prevalence rates, odds ratios (OR), and corresponding 95% confidence intervals (CI) were extracted for analysis.
resultsThe screening process identified 12 eligible studies. The meta-analysis showed that the overall prevalence of CINV in BC patients was 48% (95% CI = 0.37-0.58). Univariate analysis identified the following risk factors: age ≤ 45 years (OR = 3.21, 95% CI = 1.44-7.17) and a history of motion sickness (OR = 4.85, 95% CI = 1.65-14.30). Multivariate analysis showed that age ≤ 45 years (OR = 2.36, 95% CI = 1.78-3.14), history of motion sickness (OR = 2.05, 95% CI = 1.42-2.98), and chemotherapy cycles ≥ 3 (OR = 2.27, 95% CI = 1.28-4.04) were risk factors. In contrast, anxiety (OR = 2.74, 95% CI = 0.66-11.29) and comorbidities (OR = 1.04, 95% CI = 0.72-1.49) were not significantly associated with CINV in BC patients.
interpretationThis meta-analysis shows that the prevalence of CINV in BC patients is high. It focused on the Asian population and indicated that younger age, history of motion sickness, and more chemotherapy cycles (≥ 3) were risk factors for CINV. Targeting these risk factors may help prevent CINV in BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.